TLDR Capricor Therapeutics stock stays flat at $6.57 after Lancet publishes HOPE-3 data. The Lancet’s peer review confirms Deramiocel’s Phase 3 trial design and results. UC Davis expert calls
CAPR shares closed at $6.57 on July 28, unchanged from the prior session. The 0.00% move reflected a quiet trading day despite major clinical news breaking. The Lancet published pivotal Phase 3 HOPE-3 trial results for Capricor Therapeutics’ cell therapy Deramiocel.
Capricor Therapeutics, Inc., CAPR
Capricor Therapeutics develops cell and exosome-based therapies for rare diseases affecting patients worldwide. The company’s Deramiocel targets Duchenne muscular dystrophy, a severe genetic muscle-wasting condition. The Lancet’s peer review confirmed the trial’s design, statistical methods, and overall findings.
The published results relied on Capricor Therapeutics’ prespecified Statistical Analysis Plan version 3.0. Independent experts scrutinized every aspect before granting publication approval. This validation strengthens the scientific foundation behind Deramiocel’s regulatory submission.
The manuscript describes Deramiocel as a heart-derived cellular therapy for advanced Duchenne muscular dystrophy. Researchers conducted the HOPE-3 trial as randomized, double-blind, and placebo-controlled. This rigorous design adds credibility to Capricor Therapeutics’ clinical claims.
Craig McDonald, a physical medicine professor at UC Davis Health, led the HOPE-2 and HOPE-3 trials. He called the results a landmark moment for the Duchenne community. McDonald noted a 54 percent slowing of upper limb disease progression, with statistical significance.
This effect stands out because functional decline in Duchenne patients typically remains relentless and irreversible. HOPE-3 marks the first Phase 3 trial to show functional benefit in largely non-ambulatory patients. Concurrent cardiac improvements support a consistent treatment effect across both muscle types.
Linda Marbán, CEO of Capricor Therapeutics, emphasized the strength of the overall evidence package. She stated that publication in The Lancet further validates the clinical data collected. Marbán noted that this evidence underpins the company’s Biologics License Application.
The FDA set a PDUFA target action date of August 22 for Deramiocel’s review. Capricor Therapeutics has maintained ongoing communication with regulators throughout the process. Company leadership expressed confidence that the evidence supports eventual approval.
An Advisory Committee meeting will further discuss the trial data before a final decision. Marbán described Deramiocel as capable of changing the disease’s course for patients. The company aims to deliver the first approved cell therapy for Duchenne muscular dystrophy.
Capricor Therapeutics continues advancing its broader pipeline of cell and exosome-based treatments. The stock’s flat close suggests market participants await further regulatory clarity ahead. Upcoming decisions could significantly influence Capricor Therapeutics’ trajectory in the biotech sector.
The post Capricor Therapeutics (CAPR) Stock: Holds Steady As Lancet Publication Validates Deramiocel’s Phase 3 Success appeared first on Blockonomi.
